期刊
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 303, 期 19, 页码 1946-1953出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.619
关键词
-
资金
- Advanced Neuromodulation Systems
- AstraZeneca
- Best Practice Project Management
- Bristol-Myers Squibb/Otsuka
- Cyberonics Inc
- Forest Pharmaceuticals
- Gerson Lehrman Group
- GlaxoSmithKline
- Jazz Pharmaceuticals
- Magellan Health Services
- Merck Company
- Neuronetics
- Novartis Pharmaceuticals
- Ono Pharmaceuticals
- Organon
- Otsuka Pharmaceuticals
- Pamlab
- Pfizer
- Transcept Pharmaceuticals
- Urban Institute
- Wyeth Ayerst
- Forest Laboratories
- National Institute of Mental Health
- Stanley Medical Research Institute
- Veterans Integrated Systems Network 17
- VA North Texas Health Care System Research Corporation
- National Institutes of Health [2K24DK002818-0]
- Rosewood Corporation Chair in Biomedical Science
- [P30DK079328]
Context Patients with chronic kidney disease (CKD) experience increased rates of hospitalization and death. Depressive disorders are associated with morbidity and mortality. Whether depression contributes to poor outcomes in patients with CKD not receiving dialysis is unknown. Objective To determine whether the presence of a current major depressive episode (MDE) is associated with poorer outcomes in patients with CKD. Design, Setting, and Patients Prospective cohort study of 267 consecutively recruited outpatients with CKD (stages 2-5 and who were not receiving dialysis) at a VA medical center between May 2005 and November 2006 and followed up for 1 year. An MDE was diagnosed by blinded personnel using the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) criteria. Main Outcome Measures The primary outcome was event-free survival defined as the composite of death, dialysis initiation, or hospitalization. Secondary outcomes included each of these events assessed separately. Results Among 267 patients, 56 had a current MDE (21%) and 211 did not (79%). There were 127 composite events, 116 hospitalizations, 38 dialysis initiations, and 18 deaths. Events occurred more often in patients with an MDE compared with those without an MDE (61% vs 44%, respectively, P=.03). Four patients with missing dates of hospitalization were excluded from survival analyses. The mean (SD) time to the composite event was 206.5 (19.8) days (95% CI, 167.7-245.3 days) for those with an MDE compared with 273.3 (8.5) days (95% CI, 256.6-290.0 days) for those without an MDE (P=.003). The adjusted hazard ratio (HR) for the composite event for patients with an MDE was 1.86 (95% CI, 1.23-2.84). An MDE at baseline independently predicted progression to dialysis (HR, 3.51; 95% CI, 1.77-6.97) and hospitalization (HR, 1.90; 95% CI, 1.23-2.95). Conclusion The presence of an MDE was associated with an increased risk of poor outcomes in CKD patients who were not receiving dialysis, independent of comorbidities and kidney disease severity. JAMA. 2010; 303(19): 1946-1953
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据